Roche joins the M&A game, buy­ing gene ther­a­py pi­o­neer Spark for $4.3B

It’s of­fi­cial. Roche is join­ing the multi­bil­lion-dol­lar M&A game, ac­quir­ing a top play­er in the boom­ing gene ther­a­py busi­ness.

Im­age: Spark CEO Jef­frey Mar­raz­zo at an End­points News pan­el dur­ing the 2019 JP Mor­gan con­fer­ence Jeff Ru­mans for End­points News

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.